Zydus Lifesciences Limited to Acquire Majority Stake in Amplitude Surgical SA via Purchase Agreement with PAI Partners and Other Shareholders – Business Wire
Zydus Lifesciences Limited has announced the signing of a purchase agreement with PAI Partners and other shareholders to acquire a majority stake in Amplitude Surgical SA. This strategic acquisition marks a significant milestone for Zydus Lifesciences, as it expands its presence in the global orthopedic market. Amplitude Surgical SA is a leading French company specializing in orthopedic products, including implants, instruments, and services.
The acquisition is expected to bolster Zydus Lifesciences’ portfolio of orthopedic offerings, enabling the company to strengthen its position in the global market. Amplitude Surgical SA has a strong reputation for its high-quality products and extensive distribution network, which spans across Europe, the Americas, and Asia-Pacific. The company’s product range includes hip and knee implants, trauma products, and surgical instruments, among others.
The purchase agreement signed with PAI Partners, a preeminent private equity firm, and other shareholders of Amplitude Surgical SA, is subject to customary closing conditions, including regulatory approvals. Upon completion, Zydus Lifesciences will acquire a majority stake in Amplitude Surgical SA, while the existing management team will continue to lead the company.
Zydus Lifesciences’ acquisition of Amplitude Surgical SA aligns with its long-term strategy to expand its global footprint in the orthopedic market. The company aims to leverage Amplitude Surgical SA’s expertise and products to enhance its offerings and strengthen its presence in key markets. This acquisition will also enable Zydus Lifesciences to tap into Amplitude Surgical SA’s robust distribution network, expanding its reach to a broader customer base.
The global orthopedic market is expected to witness significant growth, driven by an increasing burden of musculoskeletal diseases, an aging population, and advancements in medical technology. Zydus Lifesciences’ acquisition of Amplitude Surgical SA positions the company to capitalize on this growth, while also enhancing its capabilities to address the evolving needs of orthopedic surgeons and patients.
Overall, the acquisition of Amplitude Surgical SA by Zydus Lifesciences Limited is a strategic move that will enable the company to strengthen its position in the global orthopedic market, expand its product offerings, and enhance its distribution capabilities. The acquisition is expected to drive growth and create long-term value for Zydus Lifesciences’ stakeholders, while also contributing to the advancement of orthopedic care globally.
Batch of Telma AM previously labeled as Not Suspect Quality (NSQ) is now reclassified as Spurious.
A recent development in the pharmaceutical industry has led to a batch of Telma AM, a medication previously classified as Not of Standard Quality (NSQ), being flagged as spurious. This means that the batch in question has been deemed to be of inferior quality, potentially counterfeit, or containing harmful substances.
The reclassification of the batch from NSQ to spurious is a significant concern, as it implies that the medication may pose a risk to patients who consume it. Spurious drugs are those that are either counterfeit, contain incorrect active ingredients, or have been tampered with, making them potentially life-threatening.
Telma AM is a medication used to treat hypertension and heart failure. It is a combination of two active ingredients, telmisartan and amlodipine, which help to lower blood pressure and reduce the risk of heart disease. However, if the medication is spurious, it may not contain the correct active ingredients or may contain harmful substances, which could have serious consequences for patients.
The flagging of the batch as spurious raises questions about the quality control measures in place during the manufacturing process. It is unclear at this stage whether the issue is limited to a single batch or if it is a more widespread problem. Regulatory authorities are likely to investigate the matter further to determine the cause of the problem and to take corrective action.
Patients who have been prescribed Telma AM are advised to exercise caution and to check their medication carefully before consuming it. They should also consult with their doctor or pharmacist if they have any concerns. In the meantime, regulatory authorities will work to identify the source of the problem and to prevent any further spurious batches from entering the market.
The use of spurious medications can have serious consequences for patients, including adverse reactions, worsening of underlying medical conditions, and even death. It is essential that regulatory authorities, manufacturers, and healthcare professionals work together to ensure that medications are safe, effective, and of high quality. This includes implementing robust quality control measures during the manufacturing process and monitoring the supply chain to prevent counterfeit or spurious medications from entering the market.
Alkem Laboratories has finalized the purchase of a 100% ownership stake in Adroit Biomed.
Alkem Laboratories, a leading pharmaceutical company, has successfully completed the acquisition of a 100% stake in Adroit Biomed, a biotechnology company. This strategic move is expected to strengthen Alkem’s presence in the biotechnology sector and expand its product portfolio.
Adroit Biomed is a research-based organization that focuses on developing innovative products and solutions for various therapeutic areas. The company has a strong research and development pipeline, with several products in different stages of development. With this acquisition, Alkem Laboratories will gain access to Adroit Biomed’s research capabilities, product portfolio, and expertise in biotechnology.
The acquisition is expected to enhance Alkem’s competitiveness in the global pharmaceutical market and provide new opportunities for growth. Alkem Laboratories has been expanding its product portfolio and capabilities through strategic acquisitions and partnerships. This acquisition is a significant step towards achieving the company’s goal of becoming a leading player in the biotechnology sector.
The terms of the acquisition were not disclosed, but it is expected to be completed in a phased manner. Alkem Laboratories will integrate Adroit Biomed’s operations and personnel into its existing business, with the aim of maximizing synergies and minimizing disruptions.
The acquisition of Adroit Biomed is part of Alkem Laboratories’ strategy to expand its presence in the biotechnology sector and to diversify its product portfolio. The company has been investing heavily in research and development and has established partnerships with various organizations to develop new products and technologies.
The completion of this acquisition is a significant milestone for Alkem Laboratories and is expected to have a positive impact on the company’s future growth and profitability. With the acquisition of Adroit Biomed, Alkem Laboratories has strengthened its position in the biotechnology sector and is well-positioned to capitalize on the growing demand for biotechnology products and services.
The acquisition is also expected to benefit Adroit Biomed’s employees, customers, and partners, as it will provide them with access to Alkem Laboratories’ global network, resources, and expertise. Overall, the acquisition of Adroit Biomed by Alkem Laboratories is a strategic move that is expected to drive growth, innovation, and success for both companies.
Sun Pharma and Moebius announce encouraging results for MM-II in treating osteoarthritis, reports Construction World
Sun Pharmaceutical Industries and Moebius Medical have announced promising results from a Phase II clinical trial for their investigational osteoarthritis treatment, MM-II. The study demonstrated significant improvements in pain reduction and functional improvement in patients with knee osteoarthritis.
The randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of MM-II in 200 patients with moderate to severe knee osteoarthritis. Patients were administered either MM-II or a placebo, and their symptoms were assessed over a 12-week period. The results showed that MM-II significantly reduced pain and improved function in patients, with a notable difference from the placebo group.
The primary endpoint of the study was the change from baseline to week 12 in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale. The WOMAC is a widely used and validated measure of osteoarthritis symptoms. The results showed that patients treated with MM-II experienced a significant reduction in pain, with a mean change from baseline of -2.3 points, compared to -1.2 points for the placebo group.
Secondary endpoints, including the WOMAC function subscale and the patient-reported outcome measure, also demonstrated significant improvements in patients treated with MM-II. The treatment was generally well-tolerated, with no significant safety concerns reported.
The positive results of this study suggest that MM-II may provide a new treatment option for patients with osteoarthritis, a debilitating condition that affects millions of people worldwide. Osteoarthritis is characterized by the breakdown of cartilage in joints, leading to pain, stiffness, and limited mobility. Current treatments for osteoarthritis are limited, and many patients do not experience adequate relief from their symptoms.
The development of MM-II is a significant step forward in the search for effective osteoarthritis treatments. Sun Pharma and Moebius Medical plan to continue development of MM-II, with the goal of bringing this promising treatment to market. The companies believe that MM-II has the potential to make a meaningful difference in the lives of patients with osteoarthritis, and they look forward to advancing the program through further clinical trials.
The success of MM-II in this Phase II trial is a testament to the innovative approach of Sun Pharma and Moebius Medical. The companies’ collaboration has resulted in a potentially breakthrough treatment for osteoarthritis, and their continued work in this area is likely to have a significant impact on the lives of patients worldwide. Overall, the promising results of this study offer new hope for patients with osteoarthritis, and demonstrate the potential of MM-II to become a valuable treatment option for this debilitating condition.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.